• Total unaudited quarterly revenue jumps 30% to $4.1M
• Robust pipeline of $62M in open proposals, with $26M in new proposals in Q3FY25
• Significant increase in API revenue and new contract wins bode well for other verticals

IDT Australia Limited (ASX: IDT) is pleased to provide an update for the three months ended 31 March 2025 (Q3FY25), which recorded further growth in total unaudited revenue and a robust sales pipeline of potential contracts. Preliminary unaudited revenue for the quarter jumped 30.4% over the previous corresponding period (pcp) to $4.1 million, with IDT securing $4.5 million in new contracts in Q3FY25 despite the start of the calendar year (financial year in the United States) being a seasonally slow period for contract signings. In addition to IDT issuing new client proposals worth a total of $25.5 million in the quarter, taking the total value of open proposals to $61.8 million, there has been a sharp increase in new contracts for the Active Pharmaceutical Ingredients (API) manufacturing vertical in the period. This provides an opportunity for IDT to secure follow-on work to produce the finished drug as a tablet or injectable. The Company's two other verticals, Advanced Therapies and Specialty Orals, are also expected to benefit from the growth in API work. While the Specialty Orals vertical experienced a temporary decline due to an oversupply issue in the medicinal cannabis market, the outlook for this vertical is bright due to growing demand for psychedelics and other drugs to treat central nervous system (CNS) disorders.

IDT is well-positioned for further growth, driven by its comprehensive end-to-end manufacturing solutions which meet increasing demand across the drug development lifecycle. The Company's ability to deliver consistent, high-quality services has resulted in a growing base of repeat work, which is translating into stronger margins and larger, more strategic contracts as the drug moves from clinical trials to commercialisation. Furthermore, Australia's global reputation as an attractive destination for drug development -- owing to its supportive regulatory environment, tax incentives, skilled workforce and robust clinical trial infrastructure -- continues to work in IDT's favour. As a market leader in this space, IDT is ideally placed to capitalise on these long-term tailwinds.